Nano-X Imaging 8/21/2026 Earnings Report

Nano-X Imaging EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.16
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Nano-X Imaging Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $5.38 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Nano-X Imaging Announcement Details

• Date: 8/21/2026
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Nano-X Imaging (NASDAQ:NNOX) is a medical technology company developing and commercializing a digital X-ray imaging platform designed to lower the cost and increase the accessibility of diagnostic imaging. Its flagship product, the Nanox.ARC, leverages a proprietary micro-electromechanical system (MEMS) based digital X-ray source and advanced image processing software to provide 2D and 3D imaging capabilities on a compact footprint. The system aims to streamline radiology workflows and facilitate point-of-care diagnostics in hospitals, clinics and outpatient settings.

The Nanox.ARC platform integrates a novel cold cathode X-ray source, which enables multiple emission points without the need for rotating anode tubes. This architecture is intended to reduce manufacturing complexity and maintenance requirements compared with conventional X-ray devices. The company’s software suite offers tools for image enhancement, storage and remote review, supporting tele-radiology applications and cloud-based archiving of patient scans.

Founded in 2018 and headquartered in Israel, Nano-X Imaging completed a business combination via a special purpose acquisition company (SPAC) that resulted in its Nasdaq listing under the ticker NNOX in 2021. The company was co-founded by industry entrepreneur Ran Poliakine, who serves as chairman, and has attracted strategic partnerships to support clinical evaluation and regulatory submissions. Nano-X has secured CE marking for head and extremity imaging and has received Breakthrough Device designation from the U.S. Food and Drug Administration for its imaging system.

Nano-X Imaging is pursuing global commercialization through master distributor agreements and direct sales channels across Europe, the Middle East and Asia-Pacific regions. Initial distribution partnerships include territories such as Japan, Saudi Arabia, Italy and Spain, with further expansion plans targeting North America and other emerging markets. The company continues to engage healthcare providers and regulatory authorities to complete clinical validations and obtain market approvals.